Now our company has strong technical force, advanced process equipment, complete testing means and broad sales network. After the existing workshops are put into production, it is estimated that the annual sales income will be 350 million yuan and the profit and tax will be 30 million yuan. In order to adjust the product structure, increase new economic growth points, and promote enterprises to become stronger and stronger, the shareholders will decide to introduce funds in various forms and intend to carry out various forms of cooperation with large pharmaceutical enterprise groups. Ways and means can be specifically negotiated, such as capital increase and share expansion, holding, acquisition of shares and debt-to-equity swaps, or investors can bring funds, bring projects, and adopt fixed-reward cooperation methods. Companies rely on various resource advantages, is willing to cooperate with well-known medical research institutions and pharmaceutical manufacturers. Chairman of the company Zhao Wenwu, general manager Zhang Lixia and all shareholders, warmly welcome domestic and foreign knowledgeable and ambitious people to come to our company to invest in the industry and seek common development!